PBF 509

Drug Profile

PBF 509

Alternative Names: PBF-509

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Palobiofarma
  • Class Antiparkinsonians
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lung cancer; Non-small cell lung cancer
  • No development reported Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 29 Oct 2015 PBF 509 licensed to Novartis worldwide
  • 01 Aug 2015 Phase-I clinical trials in Non-small cell lung cancer (Metastatic disease, Late-stage disease) in USA (PO)
  • 01 Apr 2015 Palpbiofarma files an IND application with the US FDA for Lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top